StemDisc is Shrink’s latest bioscience application of its proprietary, patent-pending, advanced plastic material called NanoShrink.
Shrink has claimed that StemDisc offers a low cost, flexible and cost effective solution for biotech researchers to conduct experiments for drug discovery, regenerative medicine and cancer research, among others.
Mark Baum, CEO of Shrink Nanotechnologies, said: “Biotech researchers, pharmaceutical companies and universities worldwide are seeking the ‘picks’ and ‘shovels’ for this generation’s stem cell ‘gold rush’. StemDisc provides those tools to accelerate cell culturing at a lower cost compared to existing protocols.
“Our patent filing on StemDisc is a part of developing an extensive intellectual property position for a number of biomedical research technologies and tools we intend to address publicly in the near future”